News and Trends 20 Jul 2021 Danish Dementia Startup Launches Amid Maturing Nordic Biotech Scene Muna Therapeutics debuted with the Danish biotech sector’s biggest-ever Series A round earlier this month. This showcases the rapid growth taking place in the biotech industry in the Nordic region. Muna Therapeutics’ €62M ($73M) investment was co-led by the Danish investor Novo Holdings through its early-stage arm Novo Seeds. The startup was first set up […] July 20, 2021 - 4 minutesmins - By Victor Kotsev Share WhatsApp Twitter Linkedin Email
News and Trends 16 Jul 2021 Multi-Million UK Life Sciences Initiative Welcomed By VC Firms Biotech venture capital firms across Europe have warmly received the launch of a €235M (£200M) UK government initiative to support the growth of promising late-stage life sciences companies. The UK’s Life Sciences Investment Programme opened to applications from fund managers this month, with the aim of providing €235M in late-stage capital and attracting at least […] July 16, 2021 - 4 minutesmins - By Anita Chakraverty Share WhatsApp Twitter Linkedin Email
News and Trends 12 Jul 2021 Sofinnova Taps into Italian Gene Therapy with Three Seed Financings The French investor Sofinnova Partners has injected a total of €6M into three Italian gene therapy companies, cementing Italy’s reputation as a European center for cell and gene therapies. Last month, the venture capitalist Sofinnova Partners used its Telethon fund to inject cash into AAVantgarde Bio, Borea Therapeutics, and Alia Therapeutics. The three firms will […] July 12, 2021 - 5 minutesmins - By Anita Chakraverty Share WhatsApp Twitter Linkedin Email
News and Trends 8 Jul 2021 The Top European Biotech Funding Rounds in June While oncology and psychedelics dominated European biotech’s biggest funding rounds last month, startup seed financing focused more on gene therapy and drug discovery. Last month saw some momentous events for Europe’s biotech heavyweights. GSK paid an impressive €524M ($625M) upfront to co-develop an immuno-oncology candidate with iTeos Therapeutics in Belgium. Meanwhile, the German antibody drug […] July 8, 2021 - 5 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Opinion 7 Jul 2021 Three Lessons an Investor Can Learn from Biotech Entrepreneurs Sofinnova Partners’ Chairman and Managing Partner, Antoine Papiernik, describes his company’s ‘Wall of Fame’ showcasing its entrepreneurs and how their years of experience provide a source of inspiration for venture capitalists. Every time I walk through our Paris office, I am greeted by a wall of photos showcasing some of the top entrepreneurial minds that […] July 7, 2021 - 7 minutesmins - By Antoine Papiernik Share WhatsApp Twitter Linkedin Email
Opinion 21 Jun 2021 A Window to the Past: Is the Biotech Investment Boom Going to Last? The biotech industry has been going through a period of fast growth in recent years. To uncover whether the current biotech investment boom will last, let’s look at what history can teach us. A window is something that opens and shuts. So the clear implication of everyone talking about a ‘public market window’ in the […] June 21, 2021 - 7 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 10 Jun 2021 The Top European Biotech Investment Rounds in May Last month saw huge biotech investment rounds dedicated to Covid-19 vaccines in Europe, including IPOs by Valneva and Vaccitech. However, a €227M (£195M) private round by the DNA sequencing giant Oxford Nanopore Technologies made the biggest splash. Last month was a difficult one for a number of public biotech companies. Biotech stock indices proved volatile […] June 10, 2021 - 4 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 25 May 2021 Delayed IPOs and Market Drops Batter Biotech Stocks Stock markets worldwide have experienced painful instability in the last few months. As a result, the European biotech market has seen stock prices falling and IPOs postponed. The Covid-19 pandemic was a major disruption for stock markets across the globe at the start of 2020. However, markets like Euronext and the tech-focused Nasdaq rallied and […] May 25, 2021 - 6 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Expert Advice 17 May 2021 How to Spend Your Biotech Startup’s Money Biotech investment rounds tend to draw big headlines, but experienced players know the real work is done in between them. Avoiding some common pitfalls can make the difference between petering out and pressing on. Managing a biotech startup means always keeping an eye towards the next financing round. But piquing the next investor’s interest requires […] May 17, 2021 - 6 minutesmins - By Mark Zipkin Share WhatsApp Twitter Linkedin Email
News and Trends 11 May 2021 ADC Approval Buoys Spirits in Cancer Treatment Space The FDA recently approved an antibody-drug conjugate drug from ADC Therapeutics as a treatment for blood cancer. This has given a major confidence boost to other European companies in the field as the deal mill picks up speed. Last month, ADC Therapeutics in Switzerland broke into the mainstream when its lead candidate Zynlonta received FDA […] May 11, 2021 - 7 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Opinion 26 Apr 2021 How Good Investor Communications Determine Success in a Covid World During the pandemic, the biotech industry has continued to complete deals, even without face-to-face interactions. Startups should leverage communication to sustain their investor relations and build strong momentum for late-stage funding rounds in the coming years. Speaking last July, the UK’s Secretary of State for Health and Social Care, Matt Hancock, said the Covid-19 pandemic […] April 26, 2021 - 6 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 1 Apr 2021 Have European Investors Missed the Exosome ‘Gold Rush’? When Oxford-based Evox Therapeutics announced its €81.1M (£69.2M) Series C round in February, it signaled that investors are taking exosome therapies seriously. But a lack of European investors in the exosome field raises the very real possibility that the best opportunities have already passed, along with the chance to build an exosome ecosystem to rival […] April 1, 2021 - 5 minutesmins - By Mark Zipkin Share WhatsApp Twitter Linkedin Email